226 related articles for article (PubMed ID: 31808886)
21. Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.
Mannis GN; Martin TG; Damon LE; Logan AC; Olin RL; Flanders MD; Ai WZ; Gaensler KM; Kaplan LD; Sayre PH; Smith CC; Wolf JL; Andreadis C
Leuk Lymphoma; 2016 Jul; 57(7):1560-6. PubMed ID: 26490487
[TBL] [Abstract][Full Text] [Related]
22. Limitation in Patient-Reported Function Is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.
Nawas MT; Andreadis C; Martin TG; Wolf JL; Ai WZ; Kaplan LD; Mannis GN; Logan AC; Damon LE; Huang CY; Olin RL
Biol Blood Marrow Transplant; 2019 Jun; 25(6):1218-1224. PubMed ID: 30708189
[TBL] [Abstract][Full Text] [Related]
23. Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients.
Vu K; Manjappa S; DiPersio JF; Gao F; Westervelt P; Vij R; Stockerl-Goldstein KE; Uy GL; Abboud CN; Schroeder MA; Fehniger TA; Cashen AF; Romee R
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1425-30. PubMed ID: 25840336
[TBL] [Abstract][Full Text] [Related]
24. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
25. Function, Survival, and Care Utilization Among Older Adults With Hematologic Malignancies.
DuMontier C; Liu MA; Murillo A; Hshieh T; Javedan H; Soiffer R; Stone RM; Driver JA; Abel GA
J Am Geriatr Soc; 2019 May; 67(5):889-897. PubMed ID: 30945759
[TBL] [Abstract][Full Text] [Related]
26. Intensive chemotherapy and reduced-intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in elderly patients.
Jackson K; Kennedy G; Mollee P; Marlton P; Morris K
Asia Pac J Clin Oncol; 2014 Sep; 10(3):246-54. PubMed ID: 24673966
[TBL] [Abstract][Full Text] [Related]
27. Definition of Unfit for Standard Acute Myeloid Leukemia Therapy.
Klepin HD
Curr Hematol Malig Rep; 2016 Dec; 11(6):537-544. PubMed ID: 27681539
[TBL] [Abstract][Full Text] [Related]
28. Pretransplant comprehensive geriatric assessment in hematopoietic cell transplantation: a single center experience.
Lin RJ; Shahrokni A; Dahi PB; Jakubowski AA; Devlin SM; Maloy MA; Robinson KS; Perales MA; Shah GL; Korc-Grodzicki B; Giralt SA
Bone Marrow Transplant; 2018 Sep; 53(9):1184-1187. PubMed ID: 29523890
[No Abstract] [Full Text] [Related]
29. Are we curing more older adults with acute myeloid leukemia with allogeneic transplantation in CR1?
Finn LE; Foran JM
Curr Opin Hematol; 2016 Mar; 23(2):95-101. PubMed ID: 26825695
[TBL] [Abstract][Full Text] [Related]
30. Initial therapy for acute myeloid leukemia in older patients: principles of care.
Bhatt VR; Gundabolu K; Koll T; Maness LJ
Leuk Lymphoma; 2018 Jan; 59(1):29-41. PubMed ID: 28573900
[TBL] [Abstract][Full Text] [Related]
31. Impact of comorbidities constituting the hematopoietic cell transplant (HCT)-comorbidity index on the outcome of patients undergoing allogeneic HCT for acute myeloid leukemia.
Khalil MMI; Lipton JH; Atenafu EG; Gupta V; Kim DD; Kuruvilla J; Viswabandya A; Messner HA; Michelis FV
Eur J Haematol; 2018 Feb; 100(2):198-205. PubMed ID: 29168234
[TBL] [Abstract][Full Text] [Related]
32. MN1, FOXP1 and hsa-miR-181a-5p as prognostic markers in acute myeloid leukemia patients treated with intensive induction chemotherapy and autologous stem cell transplantation.
Seipel K; Messerli C; Wiedemann G; Bacher U; Pabst T
Leuk Res; 2020 Feb; 89():106296. PubMed ID: 31927137
[TBL] [Abstract][Full Text] [Related]
33. Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Lee CJ; Savani BN; Mohty M; Gorin NC; Labopin M; Ruggeri A; Schmid C; Baron F; Esteve J; Giebel S; Ciceri F; Nagler A
Bone Marrow Transplant; 2019 Apr; 54(4):519-530. PubMed ID: 30104717
[TBL] [Abstract][Full Text] [Related]
34. Transplantation and Cellular Therapy for Older Adults-The MSK Approach.
Lin RJ; Dahi PB; Korc-Grodzicki B; Shahrokni A; Jakubowski AA; Giralt SA
Curr Hematol Malig Rep; 2024 Apr; 19(2):82-91. PubMed ID: 38332462
[TBL] [Abstract][Full Text] [Related]
35. The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia.
Czyz A; Nagler A
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31661875
[TBL] [Abstract][Full Text] [Related]
36. Hematopoietic Cell Transplant (HCT) in the Elderly: Myths, Controversies and Unknowns.
Al-Mansour Z; Ramanathan M; Cerny J
Drugs Aging; 2018 Dec; 35(12):1055-1064. PubMed ID: 30302674
[TBL] [Abstract][Full Text] [Related]
37. Process of allogeneic hematopoietic cell transplantation decision making for older adults.
Randall J; Keven K; Atli T; Ustun C
Bone Marrow Transplant; 2016 May; 51(5):623-8. PubMed ID: 26457910
[TBL] [Abstract][Full Text] [Related]
38. Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis.
Versluis J; Hazenberg CL; Passweg JR; van Putten WL; Maertens J; Biemond BJ; Theobald M; Graux C; Kuball J; Schouten HC; Pabst T; Löwenberg B; Ossenkoppele G; Vellenga E; Cornelissen JJ;
Lancet Haematol; 2015 Oct; 2(10):e427-36. PubMed ID: 26686044
[TBL] [Abstract][Full Text] [Related]
39. Geriatric Assessment in Older Adults with Multiple Myeloma.
Wildes TM; Tuchman SA; Klepin HD; Mikhael J; Trinkaus K; Stockerl-Goldstein K; Vij R; Colditz G
J Am Geriatr Soc; 2019 May; 67(5):987-991. PubMed ID: 30548581
[TBL] [Abstract][Full Text] [Related]
40. Inferior outcome after allogeneic transplant in first remission in high-risk AML patients who required more than two cycles of induction therapy.
Lim SJ; Lim MJ; Raptis A; Hou JZ; Farah R; Marks SM; Im A; Dorritie K; Sehgal A; Agha M; Felgar R; Lim SH
Am J Hematol; 2015 Aug; 90(8):715-8. PubMed ID: 26010177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
